Xeris Biopharma Holdings (XERS) Debt to Equity (2023 - 2025)
Historic Debt to Equity for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to -$254.9.
- Xeris Biopharma Holdings' Debt to Equity fell 4784803.74% to -$254.9 in Q3 2025 from the same period last year, while for Sep 2025 it was -$254.9, marking a year-over-year decrease of 4784803.74%. This contributed to the annual value of -$7.84 for FY2024, which is 7469.35% up from last year.
- Xeris Biopharma Holdings' Debt to Equity amounted to -$254.9 in Q3 2025, which was down 4784803.74% from -$11.33 recorded in Q2 2025.
- Over the past 5 years, Xeris Biopharma Holdings' Debt to Equity peaked at $4.53 during Q3 2023, and registered a low of -$254.9 during Q3 2025.
- Its 3-year average for Debt to Equity is -$27.82, with a median of -$0.53 in 2024.
- In the last 5 years, Xeris Biopharma Holdings' Debt to Equity surged by 7469.35% in 2024 and then tumbled by 5190527.2% in 2025.
- Quarter analysis of 3 years shows Xeris Biopharma Holdings' Debt to Equity stood at -$30.97 in 2023, then soared by 74.69% to -$7.84 in 2024, then plummeted by 3152.31% to -$254.9 in 2025.
- Its last three reported values are -$254.9 in Q3 2025, -$11.33 for Q2 2025, and -$6.54 during Q1 2025.